---
title: "CrystalGenomics and Standigm, Agree to Collaborate on Utilizing Artificial Intelligence and Structure-Based Drug Design Technologies in Drug R&D"
categories:
  - News
---

Seoul, Korea, South, June 01, 2017 --(PR.com)-- CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to apply Artificial Intelligence (AI) to the research and development of novel drugs.

Under the agreement, both parties plan to work together by combining the power of Standigm’s AI technology with CrystalGenomics’ pharmaceutical expertise with a goal to discover and develop novel drugs in the therapeutic area of cancer, rheumatoid arthritis and liver related diseases.

[Read more](http://www.pr.com/press-release/718179)
